

## AMENDMENTS


### In the Specification:

Please amend the specification as follows:

at p. 122

### ABSTRACT

Novel purine compounds of Formula 1, pharmaceutically acceptable prodrugs and salts thereof, ~~the following structure and~~ their use as fructose 1,6-bisphosphatase inhibitors is described.



Formula 1

wherein


~~— A is selected from the group consisting of  $\text{NR}^8_2$ ,  $\text{NHSO}_2\text{R}^3$ ,  $\text{OR}^5$ ,  $\text{SR}^5$ , halo, lower alkyl,  $\text{CON}(\text{R}^3)_2$ , guanidino, amidino, H, and perhaloalkyl;~~

~~— E is selected from the group consisting of H, halo, lower alkylthio, lower perhaloalkyl, lower alkyl, lower alkenyl, lower alkynyl, lower alkoxy, CN, and  $\text{NR}^7_2$ ;~~

~~— X is selected from the group consisting of alk-NR, alkylene, alkenylene, alkynylene, arylene, heteroarylene, alk-NR-alk, alk-O-alk, alk-S-alk, alk-S, alicyclicene, heteroalicyclicene, 1,1-dihaloalkylene,  $\text{C}(\text{O})$ -alk,  $\text{NR}-\text{C}(\text{O})-\text{NR}'$ ,  $\text{alk-NR}-\text{C}(\text{O})$ ,  $\text{alk}-\text{C}(\text{O})-\text{NR}$ , Ar-alk, and  $\text{alk-Ar}$ , all optionally substituted, wherein each R and R' is independently selected from H and lower alkyl, and wherein each "alk" and "Ar" is an independently selected alkylene or arylene, respectively;~~

~~Y is selected from the group consisting of H, alkyl, alkenyl, alkynyl, aryl, alicyclic, heteroalicyclic, aralkyl, aryloxyalkyl, alkoxyalkyl, C(O)R<sup>3</sup>, S(O)<sub>2</sub>R<sup>3</sup>, C(O)OR<sup>3</sup>, CONHR<sup>3</sup>, NR<sup>2</sup><sub>2</sub>, and OR<sup>3</sup>, all except H are optionally substituted;~~

~~R<sup>1</sup> is independently selected from the group consisting of H, alkyl, aryl, heteroalicyclic where the cyclic moiety contains a carbonate or thiocarbonate, C(R<sup>2</sup>)<sub>2</sub> aryl, alk aryl, C(R<sup>2</sup>)<sub>2</sub>OC(O)NR<sup>2</sup><sub>2</sub>, NR<sup>2</sup>—C(O)—R<sup>3</sup>, C(R<sup>2</sup>)<sub>2</sub>OC(O)R<sup>3</sup>, C(R<sup>2</sup>)<sub>2</sub>O—C(O)OR<sup>3</sup>, C(R<sup>2</sup>)<sub>2</sub>OC(O)SR<sup>3</sup>, alk—S—C(O)R<sup>3</sup>, alk—S—S—alkylhydroxy, and alk—S—S—S—alkylhydroxy, or together R<sup>1</sup> and R<sup>1</sup> are alk—S—S—alk to form a cyclic group, wherein each "alk" is an independently selected alkylene, or together R<sup>1</sup> and R<sup>1</sup> are~~



~~wherein~~

~~V and W are independently selected from the group consisting of hydrogen, aryl, substituted aryl, heteroaryl, substituted heteroaryl, 1-alkenyl, 1-alkynyl, and R<sup>9</sup>; or~~

~~together V and Z are connected via a chain of 3-5 atoms, only one of which can be a heteroatom, to form part of a cyclic group substituted with hydroxy, acyloxy, alkoxy, alkoxy, or aryloxy, attached to a carbon atom that is three atoms from an oxygen attached to the phosphorus; or~~

~~together V and W are connected via a chain of 3 carbon atoms to form part of a cyclic group substituted with hydroxy, acyloxy, alkoxy, alkoxy, alkylthiocarboxy, hydroxymethyl, or aryloxy, attached to a carbon atom that is three atoms from an oxygen attached to the phosphorus;~~

~~Z is selected from the group consisting of CH<sub>2</sub>OH, CH<sub>2</sub>OCOR<sup>3</sup>, CH<sub>2</sub>OC(O)SR<sup>3</sup>, CH<sub>2</sub>OCO<sub>2</sub>R<sup>3</sup>, SR<sup>3</sup>, S(O)R<sup>3</sup>, CH<sub>2</sub>N<sub>3</sub>, CH<sub>2</sub>NR<sup>2</sup><sub>2</sub>, CH<sub>2</sub>Ar, CH(Ar)OH, CH(CH=CR<sup>2</sup>)OH, CH(C≡CR<sup>2</sup>)OH, and R<sup>2</sup>;~~

~~with the provisos that:~~

~~a) V, Z, W are not all H; and~~

~~b) when Z is  $R^2$ , then at least one of V and W is not H or  $R^9$ ;~~

~~$R^2$  is selected from the group consisting of  $R^3$  and H;~~

~~$R^3$  is selected from the group consisting of alkyl, aryl, alicyclic, heteroalicyclic, and aralkyl;~~

~~$R^4$  is independently selected from the group consisting of H, lower alkyl, lower alicyclic, lower heteroalicyclic, lower aralkyl, and lower aryl;~~

~~$R^5$  is selected from the group consisting of lower alkyl, lower aryl, lower aralkyl, lower alicyclic, and lower heteroalicyclic;~~

~~$R^6$  is independently selected from the group consisting of H, and lower alkyl;~~

~~$R^7$  is independently selected from the group consisting of H, lower alkyl, lower alicyclic, lower heteroalicyclic, lower aralkyl, lower aryl, and  $C(O)R^{10}$ ;~~

~~$R^8$  is independently selected from the group consisting of H, lower alkyl, lower aralkyl, lower aryl, lower alicyclic,  $C(O)R^{10}$ , or together said  $R^8$  groups form a bidendate alkylene;~~

~~$R^9$  is selected from the group consisting of alkyl, aralkyl, alicyclic, and heteroalicyclic;~~

~~$R^{10}$  is selected from the group consisting of H, lower alkyl,  $NH_2$ , lower aryl, and lower perhaloalkyl;~~

~~$R^{11}$  is selected from the group consisting of alkyl, aryl, OH,  $NH_2$  and  $OR^3$ ; and pharmaceutically acceptable prodrugs and salts thereof.~~